The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Sir Chris Hoy hailed the fundraising as a “huge step forward” in the fight to make change. "The huge sum Paddy Power are ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Prostate cancer is one of the most common cancers in men worldwide, primarily affecting older men. The prostate is a small, walnut-shaped gland located just below the bladder and in front of the ...